Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Akebia Therapeutics's Average Total Inventories for the quarter that ended in Sep. 2024 was $22.2 Mil. Akebia Therapeutics's Revenue for the
three
months ended in Sep. 2024 was $37.4 Mil.
Akebia Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.59.
Akebia Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2024
increased
from Jun. 2024 (0.57) to Jun. 2024 (0.59)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Akebia Therapeutics's Days Inventory for the
three
months ended in Sep. 2024 was 142.94.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Akebia Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.64.
Akebia Therapeutics Inventory-to-Revenue Historical Data
The historical data trend for Akebia Therapeutics's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akebia Therapeutics's Inventory-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Akebia Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Akebia Therapeutics's Days Inventory for the
three
months ended in Sep. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Akebia Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKBA has been successfully added to your 